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New genetic technologies are transforming nervous system studies in mice, impacting fields from
neural development to the neurobiology of disease. Alongside these methodological advances,
new concepts are taking shape with respect to both vocabulary and form. Here we review aspects
of both burgeoning areas. Presented are technologies which, by co-opting site-specific recombinase
systems, enable select genes to be turned on or off in specific brain cells of otherwise undisturbed
mouse embryos or adults. Manipulated genes can be endogenous loci or inserted transgenes encod-
ing reporter, sensor, or effector molecules, making it now possible to assess not only gene function,
but also cell function, origin, fate, connectivity, and behavioral output. From these methodological
advances, a new form of molecular neuroscience is emerging that may be said to lean on the
concepts of genetic access, genetic lineage, and genetic anatomy—the three ‘‘Gs’’—much like a
general education rests on the basics of reading, ‘riting, and ‘rithmetic.Introduction
One of the enduringmysteries of biology is how the billions
of neurons in the developing brain take on specific fates
and establish connections in exactly the right place and
order. Their deployment into precise functional arrays or
circuits—including those that make possible such com-
plex activities as perception, behavior, cognition, and
memory—is governed by a vast collection of genes.
Over a third of the human genome is thought to be dedi-
cated largely or exclusively to directing the development,
maintenance, and function of the various cells and circuits
of the nervous system. Understanding which neurons de-
pend on which genes is a fundamental challenge of con-
temporary neuroscience, one made all the more arduous
by the extraordinary numbers of genes and cells involved.
Though progress has been made in pinpointing gene
products responsible for the development and functioning
of some brain structures in organisms ranging from fruit
flies to chick to mice, efforts in mammalian models such
as the mouse, which develop in utero, have presented
a thorny set of problems. An obvious obstacle has been
access: it has been difficult to manipulate the brains of
mammalian embryos in ways that do not interfere with
their development. But no longer. Over the past decade,
advances have made it almost routine to turn specific
genes on or off in selected subsets of cells either inside
an otherwise undisturbed developing mouse embryo or
inside a specific organ of a living adult mouse (for reviews
see Branda and Dymecki, 2004; Dymecki, 2000; Joyner
and Zervas, 2006; Lewandoski, 2001; Miyoshi and Fishell,
2006; Wulff and Wisden, 2005). The manipulated genes
can be exogenously engineered transgenes that have
been inserted into the mouse genome and which encode
various types of reporter, sensor, or effector molecules, or
they can be actual endogenous loci.More recently, neuroscientists have been co-opting this
rapidly evolving set of genetic methods to remarkable
ends, be it toward expanding our understanding of neural
development or adult neurological disease. For example,
developmental neurobiologists have fashioned these
genetic methods to enable tracking molecularly defined
populations of cells as they take their place in the develop-
ing mouse brain (reviewed in Branda and Dymecki, 2004;
Joyner and Zervas, 2006; Pearse and Tabin, 2006; Wing-
ate, 2005). The resulting ‘‘genetic fate maps’’ are yielding
surprising information about where in the brain specific
cells arise, journey, and ultimately take up permanent
residence, as well as about what gene products may be
involved along the way. The findings, while critical for un-
derstanding how the brain develops, could have broader
clinical implications for the diagnosis and treatment of
a variety of disorders fromdevelopmental to degenerative.
Knowing which gene products participate in or associate
with the formation and functioning of specific brain areas,
that is understanding neuroanatomy on molecular terms,
could lead to the identification of new disease markers,
drug targets, and possibly cell-type-specific gene thera-
pies, as well as to novel approaches for regenerating
specific tissue. For studying adult neurological disease,
equally exciting approaches have been crafted out of
this new mouse genetic tool box. For example, tools
have been fashioned to repair postnatally genes inherited
in a silenced form (for example, Gross et al., 2002; Guy
et al., 2007). This has made it possible to test whether
inherited neurological phenotypes are reversible in post-
natal or adult mice—knowledge critical for guiding thera-
peutic strategies.
Our purpose here is to introduce a series of techniques
that are making possible, in many ways, this burgeon-
ing field of molecular neuroanatomy. We do so in theNeuron 54, April 5, 2007 ª2007 Elsevier Inc. 17
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are taking shape with respect to both vocabulary and
form.
The ‘‘Three Gs’’
A general education rests on the basics of reading, ‘riting
and ‘rithmetic. Similarly, molecular neuroanatomy may be
said to lean on three fundamental concepts—genetic ac-
cess, genetic lineage, and genetic anatomy (reviewed in
Branda and Dymecki, 2004; Joyner and Zervas, 2006).
Just as reading makes writing and arithmetic possible,
so too the ability to construct genetic lineages and genetic
anatomies depends on the first G, genetic access.
Broadly defined, genetic access is the ability to introduce
into selected cells in the brain of living animals a genetically
encoded molecule that, when expressed, can visualize,
assay, or perturb those neurons’ development, connectiv-
ity, or function. To achieve such cell-specific effects, the
genetically encoded molecule must be paired with pro-
moter and enhancer elements active only in the specific
cell types. These transcriptional regulatory elements serve
as ’’drivers’’ of the system and are incorporated into
a transgene along with the coding sequence for the effec-
tor molecule, whose only requirement is that it be geneti-
cally encoded. Such transgene construction can be
accomplished in one of three general ways: by exploiting
isolated enhancers known to be transcriptionally active
just in the selected cells (among many, examples include
Echelard et al., 1994; Palmiter et al., 1991; Zimmerman
et al., 1994); by inserting the coding sequence into a bac-
terial artificial chromosome (BAC) that contains the rele-
vant subset of promoter and enhancer elements (Gong
et al., 2002; Heintz, 2001; Lee et al., 2001; Muyrers
et al., 1999, 2001; Valenzuela et al., 2003; Yang et al.,
1997; Zhang et al., 1998); or by introducing the coding se-
quence into the actual driver gene locus by homologous
recombination in embryonic stem cells (reviewed in Hasty
et al., 2000; Matise et al., 2000). Note that in this primer,
we use the term transgene to refer to any stretch of foreign
DNA placed into the mouse genome, whether its site of in-
sertion is random, as occurs following DNA injection into
a zygote pronucleus as a means to generate a transgenic
mouse, or whether its site of insertion is targeted to a par-
ticular locus, as occurs when the avenue to the transgenic
first exploits homologous recombination in embryonic
stemcells. The latter case is also referred to as a ‘‘knockin’’
allele.
One of themost exciting advances has involved exploit-
ing selective genetic access to deliver a particular class of
molecule, a site-specific recombinase (SSR). The body of
this primer will be devoted to describing various SSR-
based technologies. The far-reaching impact of SSRs
stems from their capacity to produce very precise DNA re-
arrangements that, depending on design parameters, can
result in deletion, insertion, inversion, or translocation of
chromosomal DNA (reviewed in Branda and Dymecki,
2004; Dymecki, 2000; Garcia-Otin and Guillou, 2006;
Nagy, 2000). What this means is that, once introduced18 Neuron 54, April 5, 2007 ª2007 Elsevier Inc.into a cell, the SSR can modify a second or target gene,
effectively turning it on or off (Figures 1A and 1B).
When coupled with a particular type of target transgene
encoding a reporter molecule, the SSR approach can be
used to trace a genetic lineage, the second ‘‘G.’’ A genetic
lineage is a population of cells identified by virtue of their
arising from a progenitor cell population that is defined
through its expression of a particular gene (Chai et al.,
2000; Dymecki and Tomasiewicz, 1998; Jiang et al., 2000;
Kimmel et al., 2000; Rodriguez and Dymecki, 2000; Zinyk
et al., 1998). Genetic lineages are identified by an ap-
proach called genetic fate mapping (for reviews see
Branda and Dymecki, 2004; Dymecki et al., 2002; Joyner
and Zervas, 2006). Briefly, driver elements are used to
both define a cell population molecularly and to express
an SSR in that cell population; SSR action then results in
permanent expression of a reporter molecule in those
cells and their descendant cells, even well after SSR ex-
pression has ceased. The target reporter has, in effect,
been transformed into an indelible cell-lineage tracer,
marking ancestors and descendants, regardless of cell
type (Figure 1C). The resulting genetic fate map owes
much of its power to two key features: first, it depicts a his-
tory of gene expression that corresponds to and possibly
regulates the development of a particular cell type; sec-
ond, it does so in a way that makes it possible to visualize,
in three dimensions, how such cell lineages assemble,
over time, into the various structures that make up the
brain (examples include Farago et al., 2006; Landsberg
et al., 2005;Machold and Fishell, 2005; Rodriguez and Dy-
mecki, 2000; Sgaier et al., 2005; Zervas et al., 2004; Zinyk
et al., 1998).
Suchmolecularly defined structures constitute a genetic
anatomy. This third ‘‘G’’ depends on our ability to link gene
expression domains (embryonic or adult) with anatomical
structures. In situ detection of mRNA or protein on brain
sections can be used to relate adult molecular expression
patterns to classical, cytoarchitectonically defined nuclei,
layers, regions, and tracts. Exciting progress is being
made on this front due to the efforts of various consortia
to systematically analyze gene expression in the nervous
system using high-throughput RNA in situ hybridization
and/or BAC::reporter transgenic methods (Gong et al.,
2003; Lein et al., 2007; Magdaleno et al., 2006; Visel
et al., 2004). Interestingly, many structures, classically de-
fined based on cytoarchitectonic features, are proving to
be heterogeneous molecularly, with sets of, rather than
single, expressed genes seeming to define individual neu-
ronal cell types.
Understanding genetic anatomy in thisway not only high-
lights genetic programs active in particular neural cell
types—crucial information when thinking about how partic-
ular cell physiologies and functions are achieved or main-
tained—but also offers opportunities for gaining genetic
access to these cells in the adult organism. The latter is of
great impact because, by providing a means to investigate
gene, cell, and/or circuit function in the adult brain, it offers
a critical entre´e for examining fundamental disease issues.
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PrimerFigure 1. Site-Specific DNA Excisions
Serve as ‘‘On-Off’’ Switches for Gene
Activity and as the Basis for Genetic
Fate Mapping
(A) Structure of a generic SSR-responsive
transgene inserted as a single copy into the
mouse genome. SSR-mediated recombination
between directly repeated SSR recognition
sites (triangles) results in deletion of intervening
transcriptional stop sequences (stop) and
consequent expression of a reporter molecule.
Depending on the type of promoter incorpo-
rated, either constitutive or tissue-specific
reporter expression can be achieved. Spatial
control of transgene activation is conferred
by the regulatory elements used to drive SSR
expression.
(B) Two prototypical SSR-basedmanipulations
of an endogenous locus: conditional gene re-
moval versus repair. Depending on recognition
site (triangle) placement, SSR-mediated exci-
sion can be exploited to remove (upper panel)
or repair (lower panel) endogenous gene se-
quences. Dark gray boxes represent untrans-
lated exon regions (UTRs); light gray boxes,
coding exons; ATG, translation initiation co-
don; TAA, translation stop codon.
(C) Illustration of how site-specific recombina-
tion can be used to study the deployment of
progenitor cells and their descendants during
development. This method is referred to as ge-
netic fate mapping. The generic SSR-respon-
sive transgene of panel (A) is modified here
(upper panel) by incorporation of a broadly ac-
tive promoter (BAP), ideally capable of driving
transgene expression in any cell type at any
stage in development such that, after a recom-
bination event in a given cell, that cell and all its
progeny cells should be marked by reporter
expression regardless of subsequent cell
differentiation. We refer to conditional target
transgenes for genetic fate mapping as ‘‘indi-
cator’’ transgenes because they indicate or
provide a permanent record of all earlier occur-
ring recombination events. Lower panel: strat-
egy for SSR-based genetic fate mapping with
development of the neural tube rendered as
a simple cylinder and progressing left to right
in each row. Top row: hypothetical gene A is
expressed transiently by progenitor cells lo-
cated in the dorsal neural tube (yellow domain)
at an early developmental stage. Middle row:
SSR-expressing transgene utilizes enhancer
elements from gene A. Bottom row: When
geneA::SSR is coupled with an indicator trans-
gene, cells expressing the SSR will activate production of the reporter molecule (for example, b-gal). Activation of reporter molecule expression is
permanent, and all cells descended from the SSR-expressing (gene A-expressing) progenitors will continue expressing the reporter, therebymarking
a genetic lineage as it contributes to different brain regions during development. Descendant cells are depicted here as blue circles.Relating embryonic (as opposed to adult) gene expres-
sion to adult anatomy is a bit trickier. It involves genetic
fate mapping, just as in delineating genetic lineages, but
the focus shifts away from simply identifying descendant
cell types and instead toward understanding the contribu-
tions that specific genetic lineages make to various ana-
tomically defined structures, such as brain nuclei, layers,
or tracts. By establishing genetic anatomies via genetic
fate mapping, it becomes possible to classify neuronal as-
semblies in the adult brain in a new way—based on the
molecular programs enacted earlier in their development
rather than solely by gross cytoarchitecture. Consideringthat many antecedent gene-expression events are for-
mative with respect to final cell function, these new ge-
netic, developmental classifications are likely to reveal
physiologically relevant neuron groupings even if the
‘‘groupings’’ are highly dispersed spatially and therefore
different from those defined based on shared position
and cytoarchitecture.
Site-Specific Recombinase Technology Figures
Central to Each ‘‘G’’
Advances in the three ‘‘Gs’’—genetic access, genetic line-
age, and genetic anatomy—have depended substantiallyNeuron 54, April 5, 2007 ª2007 Elsevier Inc. 19
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(causes recombination of the bacteriophage P1 genome)
and Flp (named for its ability to invert, or ‘‘flip,’’ a DNA
segment in S. cerevisiae) (for reviews see Branda and
Dymecki, 2004; Dymecki, 2000; Stark et al., 1992). They
have several advantages. They function well in many spe-
cies, including fruit flies (Dang and Perrimon, 1992; Golic
and Lindquist, 1989; Xu and Rubin, 1993) and mice (Dy-
mecki, 1996; Lakso et al., 1992; Orban et al., 1992; Rodri-
guez et al., 2000); they catalyze recombination between
specific DNA target sequences—loxP sites, in the case
of Cre (Hoess et al., 1982), and FRT sites, for Flp (McLeod
et al., 1986)—that are not normally found in the fly or
mouse genome; and they do so with high fidelity and with-
out the need for cofactors. Creative placement of loxP
and/or FRT sites into the mouse genome can be used to
effectively engineer a variety of predetermined modifica-
tions, including gene deletions, insertions, inversions, or
exchanges. It is the relative orientation of target sites
with respect to one another that determines the outcome
of SSR-mediated recombination (Hoess et al., 1986; and
reviewed in Branda and Dymecki, 2004; Dymecki, 2000).
For example, when target sites are arranged in a head-to-
tail fashion, the result is the excision of intervening DNA
sequences (Figures 1A and 1B), a reaction that is effec-
tively irreversible due to rapid loss of the excised (circular)
product. This simple excision, exploited most readily in the
mouse, serves as the basis for most genetic fate mapping
and conditional gene activation and inactivation strategies.
In one prototypical SSR strategy, shown in Figure 1A,
SSR-mediated excision is used to render active, i.e., re-
pair, a functionally silenced transgene. The reporter or
effector molecule encoded by the target transgene is ex-
pressed upon excision, thus illustrating how SSRs can
be used to control gene expression. Typically, such a tar-
get transgene contains three elements: (1) a gene encod-
ing the desired reporter or effector molecule, (2) an in-
serted STOP cassette that functionally silences the gene
and is flanked by loxP (floxed) or FRT sequences (flrted),
and (3) promoter/enhancer sequences capable of driving
the expression of the reporter or effector gene following
SSR-mediated recombination. Thus, expression of the
target reporter or effector gene is dependent on two
things: excisional recombination, as determined by the
cell-type-selective expression of the SSR, and on the pro-
moter/enhancer sequences incorporated to drive expres-
sion of the recombined target transgene itself. Critical to
the conditional aspect of this type of SSR-based strategy
is the effectiveness of the STOP cassette. Three are listed
here in descending order of efficiency (J.C.K. and S.D.,
unpublished data): the lox2 cassette (Sauer, 1993), con-
taining SV40 intron and polyadenylation (pA) signal se-
quences, a gratuitous ATG translation start, and 50 splice
donor signal; a concatemer of SV40 pA sequences (Awa-
tramani et al., 2001, 2003; Farago et al., 2006; Lobe et al.,
1999; Soriano, 1999; Zinyk et al., 1998); and a concatemer
of bovine growth hormome pA sequences (Awatramani
et al., 2003; Farago et al., 2006).20 Neuron 54, April 5, 2007 ª2007 Elsevier Inc.A second prototypical strategy (Figure 1B) involves first
positioning the loxP or FRT recombinase target sites
within an endogenous gene. Target sites can be posi-
tioned to either functionally silence the endogenous
gene, which can then be repaired conditionally through
SSR-mediated excision of the disrupting cassette (con-
ceptually similar to the transgene activation approach out-
lined earlier) (Figure 1B, lower scheme) (for example see
Guy et al., 2007; reviewed in Dymecki, 2000); or, as is
more common, target sites can be placed so that SSR
action results in removal of endogenous gene sequences
to create, for example, a conditional null allele (Figure 1B,
upper scheme) (Gu et al., 1994; reviewed in Branda and
Dymecki, 2004).
Transgene Activation Begets Genetic Fate Maps
that Beget Genetic Lineage Information
Fate mapping, by defining relationships between embry-
onic and adult structures, is, in general, one of the most
important tools on hand to developmental neurobiologists
and stem cell scientists. Traditionally, it has required un-
fettered access to the developing embryo for injection of
retroviral (Cepko et al., 1990; Galileo et al., 1990; Walsh
and Cepko, 1988), fluorescent (Wetts and Fraser, 1988),
or vital dye lineage tracers (Keller, 1975) or the grafting
of quail cells into chick embryos (Le Douarin, 1982), thus
making it difficult to carry out in mammals. Furthermore,
these methods used for fate mapping in nonmammalian
vertebrate systems have been limited by an inability to de-
fine, in clear molecular terms, the cell population that was
initially labeled. These drawbacks can be circumvented by
applying SSR-mediated approaches to activate reporter
molecules like b-galactosidase (b-gal) or green fluores-
cent protein (GFP) in an indelible, cell-heritable fashion—
in effect, turning these reporter molecules into lineage
tracers (Figure 1C).
Because the SSR target transgene is integrated into the
mouse genome, it is cell heritable. Should recombination
occur in a progenitor cell, all of its daughter and grand-
daughter cells will go on to inherit the target transgene in
its recombined form. This heritability feature, coupled
with the use of widely active promoter/enhancer se-
quences to drive target transgene expression once re-
combination has occurred, means that the recombined
transgene, inmost cases, will be expressed in the progeny
as well as parental progenitor cells, thus turning a simple
gene activation strategy (Figure 1A) into a fate-mapping
strategy (Figure 1C). If the target transgene promoter
and enhancer sequences are capable of driving transgene
expression in any cell type at any stage of development
(ideally), then, after a recombination event in a given cell
(Figure 1C, lower panel, bottom row, left), that cell and
all its progeny cells should be marked by reporter expres-
sion regardless of subsequent cell differentiation (Fig-
ure 1C, lower panel, bottom row, right). It is important to
note that genetic fate mapping typically tracks the fate
of a molecularly defined population of cells, as opposed
Neuron
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most standard genetic fate maps, clonal relationships
cannot be strictly discerned; rather, additional features,
described later, must be added to the genetic fate-map-
ping technology in order to resolve what are likely to be
cell clones. This contrasts the exacting clonal analyses
achievable by various retroviral infection methods (Cepko
et al., 1990; Galileo et al., 1990; Golden and Cepko, 1996;
Walsh and Cepko, 1992) that have been especially useful
in, although not limited to, avian systems.
One approach that has proven advantageous in offering
the potential to fate map most cell types has been to drive
target transgene expression via a combination of highly
active transcriptional regulatory elements (Farago et al.,
2006; Zong et al., 2005), for example, collectively using
the chicken b-actin promoter, cytomegalovirus enhancer
sequence (when paired together, they are referred to as
CAG; Niwa et al., 1991), and regulatory sequences from
the endogenous mouse Gt(ROSA)26Sor (R26) locus
(Zambrowicz et al., 1997). The R26/CAG partnership
may offer improved breadth and levels of expression by
comparison to either R26 or CAG alone (Farago et al.,
2006; Zong et al., 2005), especially in the postnatal brain.
Using broadly active promoter/enhancer elements (like
R26/CAG) to drive target transgene expression means
that the same transgene can be used to study a wide
range of cell types, rendering it a fairly universal fate-map-
ping tool. Of course, the actual range of cell types that can
be marked by a given target transgene needs to be deter-
mined empirically. For example, an approximation of
scope can be gained by analyzing tissue from an animal
in which the target transgene has been partnered with a
broadly expressed SSR transgene, such that target trans-
gene repair occurs in most, if not all, cell types, each of
which then can be sampled for robustness of reporter ex-
pression (Awatramani et al., 2001; Rodriguez et al., 2000;
Rodriguez and Dymecki, 2000; Soriano, 1999). Another
set of regulatory elements shown to be highly valuable
for driving target transgene expression in the nervous
system come from the tau gene (Kramer et al., 2006). It
is important to note that the efficiency of SSR-catalyzed
excision events varies depending on where target sites
(loxP or FRT) are placed in the mouse genome, with
some loci being more permissive than others—in this re-
gard, both R26 and tau appear to sustain efficient SSR-
mediated stop-cassette removal.
In general, we prefer referring to conditional target
transgenes for genetic fate mapping as conditional ‘‘indi-
cator’’ transgenes or alleles, both to distinguish them from
more conventional, constitutively driven (nonconditional)
promoter::reporter transgenes and to emphasize that the
target transgene, through reporter expression, serves to
‘‘indicate’’ or provide a permanent record of all earlier oc-
curring recombination events. These sorts of genetic fate
maps have been described as ‘‘cumulative’’ because
such a map will include any cell that has ever in its history
expressed the SSR; if the SSR driver is dynamically ex-
pressed over space and time, as embryonic developmentprogresses, new populations of expressing cells and their
descendants will become successively incorporated in
the fate map.
Depending on the type of reporter molecule encoded by
the indicator transgene, different features of the mapped
cell population may be uncovered in addition to their
genetic history. For example, incorporating into the target
indicator transgene a nuclear-localized version of the re-
porter molecule b-galactosidase (nb-gal) allows one to vi-
sualize individual cells in a highly sensitive way. Cytoplas-
mic or membrane-localized reporters, on the other hand,
often do not allow for such resolution, especially when
cells are tightly clustered. nb-gal can further help deter-
mine the identity of final progeny cells through colocaliza-
tion with transcription factors that are capable of serving
as cell identity markers. For resolving cell morphology, in-
cluding axonal projections, it is helpful to employ a reporter
molecule capable of revealing cell shape by virtue of either
filling or outlining that cell. This can be achieved by many
of the standard cytoplasmic reporters such as GFP, or by
membrane-tethered reporter molecules such as alkaline
phosphatase or farnesylated (or myristylated) GFP. En-
dogenously fluorescing protein reporters such as GFP
may offer the further possibility of visualizing dynamic
changes in live cell morphology and position andmay per-
mit electrophysiology in cultured brain slices or explants.
Indeed, as quickly as new reporter molecules are being
developed (Giepmans et al., 2006; Miyawaki, 2003a,
2003b, 2005; Shaner et al., 2004), they are being incorpo-
rated into Cre- or Flp-responsive indicator transgenes.
An important strength of this genetic fate-mapping
approach worth emphasizing is that once an indicator
transgene has been ‘‘activated’’ by SSR-mediated recom-
bination, the encoded reporter molecule is expressed
constitutively by that lineage from that point onward.
This feature serves to ensure relatively robust marking of
descendant cells regardless of cell type or developmental
stage; for example, it is typically possible to visualize line-
age contributions to adult structures despite the extensive
elapse in time between the initial (embryonic) recombina-
tion event and the actual (adult) tissue analysis. By con-
trast, this is not always the case when certain surrogate
genetic fate-mapping approaches are used, for example,
when using perdurance of a reporter molecule that, at an
earlier time point, was expressed from a nonconditional,
transiently active promoter::reporter transgene or knockin
allele. The ‘‘fate maps’’ resulting from this surrogate type
of approach, in the strictest sense, may not be completely
accurate because some lineages may be missed due to
their more rapid elimination of the residual reporter mole-
cules and/or lower starting level of reporter expression.
Further, if (nonconditional) reporter knockin alleles are be-
ing exploited that are null for the endogenous gene prod-
uct, attention must also be given toward understanding
whether allele expression is regulated by the endoge-
nously encoded gene product, for example, if it is a tran-
scription factor that positively regulates/sustains its own
expression. In this case, homozygous reporter knockinNeuron 54, April 5, 2007 ª2007 Elsevier Inc. 21
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may more rapidly extinguish reporter expression than het-
erozygotes or wild-type animals. The reduction in reporter
levels could result in an inability to detect whatever scant
reporter molecules remain, resulting in erroneous exclu-
sion of certain cells from a fate map and thus compromis-
ing the accuracy of the ‘‘fate map.’’
Having reviewed the major parameters surrounding tar-
get indicator transgenes, there are considerations to be
made with respect to the SSR, especially Flp. There are
three variants of Flp that have been employed in mice—
enhanced Flp (Flpe), Flp-wt, and low-activity Flp (FlpL).
Taken together, the trio collectively spans greater than a
10-fold range in activity in mice (Awatramani et al., 2003;
Farago et al., 2006; Landsberg et al., 2005; Rodriguez
et al., 2000; Rodriguez and Dymecki, 2000). Enhanced
Flp (Flpe) harbors four point mutations that together con-
fer increased thermostability while maintaining normal tar-
get (FRT) specificity (Buchholz et al., 1998). To date, Flpe
has been shown to function in mice with similar efficacy as
Cre. For example, the cell populations fate mapped using
Wnt1::cre (Danielian et al., 1998; Jiang et al., 2000) and
Pet1::cre (Scott et al., 2005) transgenics are mapped
with similar efficiencies by Wnt1::Flpe and Pet1::Flpe
transgenics (Awatramani et al., 2003; Farago et al.,
2006; Landsberg et al., 2005; A. Farago, N. Hunter, P. Jen-
sen, and S.M.D., unpublished data)—the Flpe-based set
did not fall short. Still, it is worth noting that Flpe may
not perform as well as Cre in cultured mouse embryonic
stem cells (Schaft et al., 2001); toward improving Flp activ-
ity in ES cells, a mouse codon-optimized form of Flp called
Flpo has recently been generated (Raymond and Soriano,
2007).
In contrast to the very robust nature of Flpe in vivo is the
modest activity exhibited by the variant FlpL (Landsberg
et al., 2005; Rodriguez and Dymecki, 2000). FlpL contains
a single amino-acid substitution that renders the recombi-
nase thermolabile (Buchholz et al., 1996), resulting in at
least a 5-fold reduction in recombinase activity from
wild-type (Flp-wt). At first glance, FlpL may appear to
have little utility, but it turns out that, alongside Flpe, it
can be exploited to achieve a range of cellular resolution
in fate-mapping studies. For example, parallel use of
FlpL and Flpe has led to the first evidence that the germi-
nal zone called the hindbrain rhombic lip can be fate map-
ped into two broad dorsoventral domains that give rise to
different neurononal cell types (Landsberg et al., 2005;
Rodriguez and Dymecki, 2000). These ‘‘Flpe/FlpL com-
parative fate mapping’’ studies exploited the gradient of
Wnt1 expression that demarcates the hindbrain rhombic
lip dorsal-to-ventral. As a consequence of this gradient,
a smaller dorsal region of the hindbrain rhombic lip was
marked and fate mapped using a Wnt1::FlpL transgene
(capable of inducing recombination in Wnt1 mRNAhigh
cells only) than one using aWnt1::Flpe transgene (capable
of inducing recombination both in Wnt1 mRNAlow and
Wnt1 mRNAhigh cells). These experiments led to the find-
ing that the brainstem nuclei that project to different target22 Neuron 54, April 5, 2007 ª2007 Elsevier Inc.neurons in the cerebellar cortex actually originate from
molecularly and spatially distinct progenitor-cell popula-
tions in the hindbrain rhombic lip (Landsberg et al.,
2005; Rodriguez and Dymecki, 2000). These findings
were then substantiated on fate mapping other gene-
expression domains, likeMath1, that subdivide dorsoven-
trally the Wnt1 domain (Landsberg et al., 2005; Machold
and Fishell, 2005; Wang et al., 2005).
As mentioned above and at the beginning of this primer,
selective SSR delivery involves exploiting cell-type re-
stricted promoter and enhancer elements as drivers
(in the above example, elements from the Wnt1 gene;
Echelard et al., 1994). This is accomplished either by em-
ploying conventional transgenic methods (construct size
typically <20 kb), BAC transgenic strategies (constructs
typically around 200 kb), or knockin approaches; choice
of method is driven by experimental need and availability
of isolated DNA elements. For example, knockin ap-
proaches typically offer the greatest fidelity in matching
SSR expression to that of the endogenous gene of inter-
est. Further, if SSR insertion by knock in is designed to si-
lence the endogenous gene, then homozygotes can be
used in genetic fate-mapping strategies to reveal how
cell fate may change in the absence of that gene product;
a downside, though, would be if heterozgotes exhibit
haploinsufficiency, thereby precluding generation of the
needed wild-type fate map. A possible way to circumvent
haploinsufficiency is to knock in the SSR-encoding se-
quence, preceded by an internal ribosome entry sequence
(IRES), into the 30 untranslated region of the gene of inter-
est; a bicistronic transcript is produced encoding the en-
dogenous gene product followed by the SSR. While this
approach has been successful (Lee et al., 2000), lower
than desirable SSR levels may result in some cases, com-
promising recombination efficiency and therefore the abil-
ity tomark and track all cells arising from the gene-expres-
sion domain—especially vulnerable would be cells that
normally express the endogenous gene at lower levels.
Transgenic approaches (conventional and BAC) avoid
haploinsuffiency issues, as no endogenous gene is typi-
cally disrupted. BAC transgenics are quite powerful in
that, for most genes, a BAC can be identified that contains
all necessary regulatory elements to confer normal gene
expression and because they are not subject typically to
the strong position effects resulting in transgene silencing
or misexpression that can plague conventional constructs
(Heintz, 2001). An advantage of conventional transgenics
is that they permit the use of isolated enhancer elements
as drivers, should they be available, such that SSR ex-
pression can be delivered to just a subset of an otherwise
larger gene-expressing cell population (Zinyk et al., 1998).
Regardless of approach taken, it is critical to establish the
extent to which SSR expression matches the expected
driver gene expression profile, and the extent to which in-
dicator transgene recombination (reporter expression)
matches the initial driver gene expression profile—later
they will diverge because the reporter expression is cumu-
latively and permanently tracking all cells that ever in their
Neuron
Primerhistory expressed the driver gene, whereas the driver
gene expression is transient (Figure 1C). Further, it is cru-
cial to determine whether there is any unexpected ectopic
SSR expression, as this would confound subsequent fate-
mapping studies by switching on the lineage tracer in un-
related cells that would be erroneously interpreted as part
of (or lumped into) a given lineage. It is equally critical to
assess whether the SSR is capable of activating reporter
expression (through indicator transgene recombination)
in all driver gene-expressing cells, even low expressors;
this is especially important, for example, if the SSR is ex-
pressed downstream of an IRES.
Through careful use of Cre- and Flp-mediated tech-
niques, our ability to define genetically related cell popula-
tions and lineages is growing exponentially. Resulting fate
maps are revealing developmental homologies not only
among various brain structures (Chizhikov et al., 2006;
Farago et al., 2006; Landsberg et al., 2005; Machold and
Fishell, 2005; Nichols and Bruce, 2006; Sgaier et al.,
2005; Wang et al., 2005) but also among structures as dis-
parate as the mid/hindbrain and limb (Guo et al., 2003;
Kimmel et al., 2000; Zervas et al., 2004). Moreover, possi-
ble roles of gene products in development are being sug-
gested and can be tested in gene loss-of-function exper-
iments; how certain genemodifications alter themigratory
routes and ultimate fate of specific cell types can now be
assayed directly.
Expanding the mouse toolkit further may be two addi-
tional recombinase systems, both of which have shown
promise in mammalian cell culture (Andreas et al., 2002;
Belteki et al., 2003; Sauer and McDermott, 2004). The first
is a close relative of Cre, called Dre for D6 site-specific
recombinase. Dre is encoded by the bacteriophage D6
genome and recognizes a DNA target site called rox
(Sauer and McDermott, 2004). The second is fC31, a re-
combinase fromStreptomyces lividans, for which amouse
codon-opitimized version, fC31o, has recently been syn-
thesized and shown effective in mouse embryonic stem
cells (Raymond and Soriano, 2007). It is exciting to ponder
all the possible new applications that might be afforded by
having additional SSRs for use in mice.
Resolving Genetic Sublineages—Improving the
Where and When of Genetic Fate Mapping
Despite the molecular precision afforded by genetic fate
mapping, many biological questions remain unanswer-
able because of the broad extent of cell types marked
even by a single gene-expression domain. For example,
spatially, embryonic gene-expression domains commonly
restrict along one axis of a tissue or germinal zone but
extend along the orthogonal axes (Figure 2A). This more
expansive dimension will often intersect or overlap with
multiple other gene-expression domains such that it
actually contains multiple uniquely coded molecular sub-
populations (Awatramani et al., 2003; Farago et al.,
2006; Lumsden and Krumlauf, 1996) (Figure 2A). Re-
solving these subpopulations and their specific descen-
dant lineages (and thus the relationship between thiscombination of expressed genes and future cell fate)
is not possible using the genetic fate-mapping ap-
proaches presented so far. Resolution in genetic fate
mapping could also be improved along the temporal
axis. Genesmay be expressed in different cell populations
at different times, or they may be constitutively expressed
in a given cell population for an extended time period,
such as may occur in a germinal zone during a period in
which different cell types arise. Resolving the temporal
aspects of lineage allocation, for example, from such a
molecularly defined germinal zone is not possible by stan-
dard genetic fate mapping, as the approach is cumulative
in nature.
The need to better distinguish genetic lineages spatially
and temporally has driven the development of more so-
phisticated SSR-based tools. Two general types of ad-
vances are presented below: intersectional genetic fate
mapping (Awatramani et al., 2003; Farago et al., 2006)
and genetic inducible fate mapping (GIFM; reviewed in
Joyner and Zervas, 2006). In principle, each has the
potential to provide order-of-magnitude improvements in
the ability to select cells for fate mapping and to visualize
them clearly.
Improving Selectivity Using Intersectional
and Subtractive Genetic Methods
For intersectional genetic fate mapping, two SSRs, Cre
and Flpe, are paired in a dual recombinase-mediated
transgene activation paradigm (Figure 2B) (Awatramani
et al., 2003; Farago et al., 2006; reviewed in Branda and
Dymecki, 2004; Joyner and Zervas, 2006; Miyoshi and
Fishell, 2006). Lineage-tracer expression (GFP in Figures
2B–2D) is switched-on only in cells that have undergone
two genetic events in their history, one mediated by Cre
(and therefore driver gene A) and the other by Flpe (and
therefore driver gene B). Only those cells lying at the inter-
section of the two gene-expression domains (A and B) will
activate lineage-tracer expression (Figures 2B–2D, GFP-
expressing cells). By mapping cell lineages based on the
expression of gene pairs rather than of a single gene, it
is possible to begin defining combinatorial gene-expres-
sion codes that associate with the development of partic-
ular cell types (Figure 2D). It can also lead to the identifica-
tion of smaller subpopulations of genetically defined cells,
thus improving upon the first G, genetic access. The com-
bination of expressed genes (eg., driver gene A and driver
gene B) does not have to coincide temporally. The two
genes may be expressed at different times in a cell’s de-
velopmental history, with activation of the intersectional
lineage tracer (GFP in Figure 3) occurring only after the
second recombination event has been completed. This
means that temporal, as well as spatial, resolution in line-
age allocation can be improved.
In addition to fate mapping intersecting Cre/Flpe cell
subpopulations (green cells in Figures 2B–2D), the
methodology can be engineered to allow simultaneous
tracing of Cre/non-Flpe lineages (Figure 2C, blue nb-gal
cells). These lineages are referred to as ‘‘subtractive’’Neuron 54, April 5, 2007 ª2007 Elsevier Inc. 23
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PrimerFigure 3. Nonconcurrent Driver Genes Add Temporal Resolution to Intersectional Fate Maps
Development of the neural tube is again rendered as a simple cylinder progressing left to right in each row. Top row: gene A drives transient Flpe
expression in progenitor cells located in the dorsal neural tube (yellow domain) at an early developmental stage. Middle row: gene B drives transient
cre expression in a population of later-stage progenitor cells located at a particular AP level of the neural tube (pink domain). Bottom row: when
geneA::Flpe and geneB::cre are coupled with a dual recombinase-responsive indicator allele (FP configuration), expression of nb-gal, as a lineage
tracer of geneA-expressing progenitor cells, is activated first. Cells with a history of gene A expression that go on to express gene B, and therefore
cre, will, following Cre-mediated recombination, turn off nb-gal expression and turn on GFP expression (the intersectional population).populations because they are what remains when Cre/
Flpe-intersecting cells are subtracted from the Cre-only-
expressingdomain (Faragoet al., 2006). Thedual recombi-
nase-responsive target transgene can additionally be
engineered such that the subtractive population is the re-
verseFlpe/non-Crepopulation; it simply requires changing
the order of floxed and flrted cassettes (Figure 2C).
Using two recombinases simultaneously for intersec-
tional and subtractive genetic fatemapping can be a highlyefficient method for marking progenitor cells lying at the
intersection of two gene-expression domains, as
demonstrated in recent developmental studies of the
brainstem (Awatramani et al., 2003; Farago et al., 2006).
For example, using the PF strategy schematized in
Figure 2C, the GFP-positive intersectional domain was
found to exhibit few to no nb-gal-expressing cells, while
nearly all of the cells in the Cre-only domain are b-gal+,
indicating nearly 100% efficiency of Flpe-mediatedFigure 2. Intersectional and Subtractive Genetic Fate-Mapping Strategy and an Enabling Prototypical Dual
Recombinase-Responsive Indicator Allele
(A) Multiple uniquely coded molecular subdomains may comprise a single gene-expression domain. Shown are schematics of the neural tube (gray
cylinder), with different gene-expression domains depicted in different colors. The expression domain for hypothetical gene A (yellow) restricts along
the dorsoventral (DV) axis but extends along the anteroposterior (AP) axis; by contrast, the expression domains for genes B (pink) and C (red) restrict
along the AP axis but extend along the DV axis. Thus, the gene A expression domain (yellow) is subdivided into threemolecularly distinct subdomains:
one in which genes A andB are coexpressed (tan domain); another in which genes A andC are coexpressed (orange domain), and finally, that territory
(yellow) marked by gene A expression, but not B or C. Similarly, both the gene B and C expression domains are each subdivided.
(B) Structure of a prototypical dual recombinase (Cre and Flpe)-responsive indicator allele. In contrast to a single recombinase-responsive indicator
allele (Figure 1C), a dual recombinase-responsive indicator allele has two stop cassettes, one flanked by directly oriented loxP sites (triangles) and the
other by FRT sites (vertically oriented rectangles). Cre-mediated stop cassette removal results in expression of nb-gal, while the remaining FRT-
flanked stop cassette prevents GFP expression. Following removal of both stop cassettes, requiring Cre- and Flpe-mediated excisions, GFP expres-
sion is turned on and nb-gal expression off.
(C) Illustration of intersectional and subtractive populations and the latter dependency on stop-cassette order. In the ‘‘PF’’ configured allele, the loxP-
flanked stop cassette precedes the FRT-flanked cassette (left panel), while the reciprocal order characterizes the ‘‘FP’’ configuration (right panel).
Shown are schematics of the neural tube (gray cylinder), with the expression domain for hypothetical gene A and Flpe recombinase (yellow) restricting
along the dorsoventral (DV) axis but extending along the anteroposterior (AP) axis (top row); in contrast, the expression domain for gene B (pink) re-
stricts along the AP axis but extends along the DV axis (middle row). When geneA::Flpe and geneB::cre are coupled with a PF dual recombinase-
responsive indicator allele (bottom row, left), cells expressing cre and Flpe activate production of GFP (green domain, intersectional population) while
cells expressing only cre activate production of nb-gal (blue domain, subtractive population). When geneA::Flpe and geneB::cre are coupled with an
FP configured allele (bottom row, right), cells expressing cre and Flpe still activate production of GFP in the same intersectional population (green
domain) but now cells expressing only Flpe (rather than cre) activate production of nb-gal (blue domain, new subtractive population).
(D) Illustration of the selective fate mapping achievable using an intersectional and subtractive approach. Development of the neural tube is again
rendered as a simple cylinder progressing left to right in each row. Top row: gene A drives transient Flpe expression in progenitor cells located in
the dorsal neural tube (yellow domain) at an early developmental stage. Middle row: gene B drives transient cre expression in progenitor cells located
at a particular AP level of the neural tube at an early developmental stage (pink domain). Bottom row: when geneA::Flpe and geneB::cre are coupled
with a dual recombinase-responsive indicator allele (FP configuration), cells expressing Flpe and cre activate production of GFP, while cells express-
ing only Flpe activate production of nb-gal. Activation of reporter molecule expression is permanent, and all cells descended from Flpe-expressing or
Flpe- and cre-expressing progenitors will continue expressing the blue or green marker, respectively. Descendant cells from the intersectional do-
main are denoted by green circles, those from the subtractive population by blue circles.Neuron 54, April 5, 2007 ª2007 Elsevier Inc. 25
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Primerrecombination within the intersectional domain and
Cre-mediated recombination in both the intersectional
and subtractive domains (Farago et al., 2006). Another
critical factor in this approach is that the reporter molecule
associated with the subtractive population (nb-gal in this
example) has a relatively short half-life. This ensures that
the subtractive reporter (nb-gal) will not be detected in in-
tersectional descendants (eg., GFP+ cells), which could
be the case even after excision of the coding sequence
if the subtractive reporter half-life was long. This would di-
minish the resolution of the subtractive strategy because it
would mean that some of the intersectional cells could be
lumped into the subtractive fatemap if only the subtractive
reporter signal (e.g., nb-gal) was analyzed. Importantly,
the dual recombinase-responsive indicator alleles gener-
ated to date show complete elimination of the subtractive
reporter molecule (a particular form of nb-gal) in less than
72 hr of coding-sequence excision—earlier time points
were not examined, so the half-life could be even shorter
(Farago et al., 2006). Importantly, using a reporter mole-
cule with a relatively short half-life does not compromise
one’s ability to visualize the desired true subtractive line-
ages, because in those cells the reporter molecule con-
tinues to be expressed constitutively, for example from
R26/CAG sequences.
Using this intersectional and subtractive approach to
study brainstem progenitors, we have shown recently
that the cochlear nuclear complex, the entry point for all
central auditory processing, is assembled from molecu-
larly distinct progenitor-cell subpopulations arrayed as
rostrocaudal microdomains within and outside the hind-
brain (lower) rhombic lip (Farago et al., 2006). This work
also uncovered surprising parallels and unexpected
distinctions between the development of the brainstem
auditory and cerebellar systems.
On a practical level, dual recombinase-responsive indi-
cator transgenes harbor an additional advantage. Three
different mouse lines can result from one initial transgene
construction and strain generation: one dual recombi-
nase-responsive indicator line and two derivative single
recombinase-responsive lines. The latter two are readily
generated through germline deletion of either the loxP-
or FRT-flanked cassette (Farago et al., 2006).
Genetic Inducible Fate Mapping
A second means by which cell-type selectivity can be en-
hanced is through genetic inducible fate mapping (GIFM,
Joyner and Zervas, 2006) (Ahn and Joyner, 2004; Guo
et al., 2003; Harfe et al., 2004; Kimmel et al., 2000; Zervas
et al., 2004; Zirlinger et al., 2002; reviewed in Branda and
Dymecki, 2004; Joyner and Zervas, 2006; Miyoshi and
Fishell, 2006). This approach, which depends on ligand-
regulated forms of Cre or Flpe, offers a means to tempo-
rally control SSR activity. For example, it can allow SSR-
mediated recombination to be targeted only to those cells
responsible for the late aspects of a dynamic or extended
gene-expression profile. In this approach, the SSR is
fused to an estrogen receptor (ER) ligand-binding domain26 Neuron 54, April 5, 2007 ª2007 Elsevier Inc.(LBD) that has beenmutated, rendering it insensitive to the
natural ligand 17b-estradiol at physiological concentra-
tions but responsive to the synthetic ligand 4-hydroxyta-
moxifen (4-OHT) (Brocard et al., 1997; Danielian et al.,
1998, 1993; Feil et al., 1996; Logie and Stewart, 1995;
Metzger et al., 1995; Schwenk et al., 1998). Temporal con-
trol in this system occurs as follows. In the absence of
4-OHT, the ER-LBD domain sequesters the SSR into
a cytoplasmic Hsp90 complex. Upon 4-OHT binding, the
ER-LBD undergoes a conformational change that frees
it, along with the fused SSR, to enter the nucleus, where
it can mediate recombination at target sites previously en-
gineered into the genome (Figure 4). At least three different
mutant ER-LBDs are available (reviewed in Branda and
Dymecki, 2004; Joyner and Zervas, 2006; Metzger and
Chambon, 2001); the most sensitive one for both nuclear
translocation and recombinase activity appears to be ahu-
man ER variant harboring three point mutations, referred
to as ERT2 (Feil et al., 1997; Imai et al., 2001; Indra et al.,
1999; Kimmel et al., 2000; Seibler et al., 2003). CreERT2
(Imai et al., 2001; Indra et al., 1999; Kimmel et al., 2000;
Seibler et al., 2003) and FlpeERT2 (Hunter et al., 2005) fu-
sions have been generated, and both have been shown to
be effective in vivo. Anecdotally, it appears that CreERT2
may outperform FLPeERT2 when expressed at low levels
(N.L. Hunter and S.M.D., unpublished data), despite the
fact that the constitutive forms, Cre and Flpe, show com-
parably robust activity in vivo. Also being developed are
SSR fusions to mutant forms of the progesterone receptor
LBD (e.g., *PR) (Kellendonk et al., 1996, 1999). Because
*PR activation is regulated by the synthetic steroid
RU486 rather than 4-OHT, it, together with ERT2, presents
the possibility of inducing two genetic manipulations in
one animal, for example, one regulated by RU486/Cre*PR
and the other by 4-OHT/FlpeERT2.
In this inducible strategy, the window of opportunity for
recombination events—and thus the degree to which
temporal resolution can be provided—is determined
by the half-life of 4-OHT, which in mice appears to
be 24 hr. Although 4-OHT is the active inducer, its pre-
cursor tamoxifen is both easier to work with (due to its bet-
ter solubility properties) and less costly and is typically the
reagent used. Hepatic conversion of tamoxifen to 4-OHT
takes 6–12 hr in vivo, resulting in an initial lag between
administration of tamoxifen and onset of recombinase-
mediated target-gene recombination. The 6–12 hr lag
is followed by an24 hr window during which recombina-
tion is catalyzed (Hayashi and McMahon, 2002; Hunter
et al., 2005; Kimmel et al., 2000; Zervas et al., 2004;
Zirlinger et al., 2002). This schedule is consistent with
well-established tamoxifen pharmacokinetics in rodents
(Robinson et al., 1991). Taking this schedule into account,
various administration paradigms may be employed
depending on the experimental goal. These range from
single doses administered to pregnant females (2–14 mg
tamoxifen/40 g mouse), in order to induce recombination
in embryos within a relatively tight temporal developmen-
tal window, to multiple consecutive daily doses in adult
Neuron
PrimerFigure 4. Addressing Temporal Aspects of Lineage Allocation by Controlling SSR Activity
(A) Schematic of a transgene encoding the recombinase-steroid fusion protein, SSR-ERT2, whose activity is regulated posttranslationally by the ligand
4-hydroxy tamoxifen (4-OHT, orange circle).
(B) Inducible recombination and cell marking using SSR-ERT2. In the absence of 4-OHT, SSR-ERT2 is inactive due to sequestration of the fusion
protein into an Hsp90 complex. Binding of 4-OHT to SSR-ERT2 results in a conformational change that disrupts the Hsp90 interaction, freeing the
recombinase to enter the cell nucleus and mediate recombination at its target sites (triangles) positioned within an indicator transgene. Excisional
recombination renders cells positive for reporter expression (for example, cytoplasmic b-gal as indicated in dark blue).
(C) Cumulative versus inducible genetic fatemapping. Development of the neural tube is again rendered as simple cylinders progressing left to right in
each row. Cumulative genetic fate mapping is schematized in the top two rows, much as done previously in Figure 1C. Top row: transient, midges-
tation expression of cre recombinase in progenitor cells of the dorsal neural tube defined by their expression of gene A. Second row: activation of
nb-gal, for example, as a lineage tracer in all cells that ever in their history expressed gene A::cre. Inducible genetic fate mapping is schematized
in the bottom two rows. Third row: transient, midgestation expression of SSR-ERT2 in progenitor cells of the dorsal neural tube defined by expression
of gene A. Bottom row: induction of recombinase activity and consequent indicator transgene expression following administration of 4-OHT permits
selective tracking of late-emerging cohorts (blue triangles) in virtual isolation.animals, with the goal of maximizing recombination after
bypassing earlier, possibly confounding, aspects of the
gene-expression profile. Low doses of tamoxifen may
even permit the marking of single cells, allowing for clonal
analysis (Legue and Nicolas, 2005). A technique called
mosaic analysis with double markers (MADM) also per-mits clonal analysis by relying on rare SSR-mediated
translocation events between two homologous chromo-
somes during theG2 phase of the cell cycle; X segregation
of the recombined chromosomes during mitosis then re-
sults in two daughter cells each expressing one or the
other marker (Zong et al., 2005).Neuron 54, April 5, 2007 ª2007 Elsevier Inc. 27
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note that tamoxifen, when administered at high doses,
can kill the developing embryo. This lethality is probably
due to some binding of 4-OHT to endogenous estrogen
receptors, which may interfere with placental develop-
ment and/or function or with the progression of labor
and delivery. Such interference can lead to the loss of
just those embryos needed for study. Establishing doses
of tamoxifen that maximize recombination at the desired
embryonic stage while keeping unwanted side effects to
a minimum is critical. Inbred strains appear particularly
sensitive to tamoxifen dose as compared to outbred
Swiss Webster mice, for example (Joyner and Zervas,
2006). Coadministration of progesterone with high tamox-
ifen doses also appears to improve litter viability (Joyner
and Zervas, 2006). Other important variables include ges-
tational age, with later-stage embryos better able to toler-
ate higher tamoxifen doses; and levels of expressed SSR-
ERT2 protein, with higher amounts better able to catalyze
recombination at lower tamoxifen levels. While higher
amounts of SSR-ERT2 expression can be helpful, if too
high, the capacity for tight inducibility may be compro-
mised—the cell’s hsp90 sequestration system may be
overwhelmed, which could result in unwanted recombina-
tion even in the absence of tamoxifen. The take-home
lesson is that it may be necessary to screen many trans-
genic mouse lines in order to identify one that expresses
the SSR-ERT2 at suitable levels.
When applying inducible genetic fate mapping, it is crit-
ical to establish the extent to which expression of the re-
porter molecule (via activation of an indicator transgene)
matches the expected driver gene-expression profile be-
tween 24–48 hr after tamoxifen administration. The degree
ofmatchingwill determinewhethermost or only a stochas-
tic subset of the highest expressors can be tracked. Once
these parameters are set, it should be possible to visualize
the fate of these cells at any later time point. The resulting
fate map will mark just those cells that have emerged from
a gene-expression domain during a particular 24 hr win-
dow. In other words, it can provide a picture of the various
cell types produced successively from a single gene-
expression domain (Machold and Fishell, 2005; Sgaier
et al., 2005; Zervas et al., 2004).
In addition to studying how progeny cells deploy from
germinal zones as a function of time during embryogene-
sis, GIFM has also been used to identify and study adult
neural stem cells (Ahn and Joyner, 2005). At late embry-
onic stages, it appears that quiescent neural stem cells
are set aside in the subventricular zone of the lateral ven-
tricles and in the subgranular zone of the dentate gyrus
and are regulated by Sonic hedgehog. These neural
stem cells appear capable of self-renewal for at least a
year and of generating multiple cell types over that time.
While intersectional and subtractive genetic fate map-
ping and genetic inducible fate mapping are important
stand-alone tools, it is exciting to ponder the resolution
in lineage mapping that might be achieved by incorporat-
ing an SSR-ERT2 fusion into an intersectional and subtrac-28 Neuron 54, April 5, 2007 ª2007 Elsevier Inc.tive genetic fate-mapping strategy. Moreover, both of
these approaches benefit greatly by the ever-expanding
number of genes whose expression has been ascertained
within the developing and mature nervous system (Gong
et al., 2003; Lein et al., 2007; Magdaleno et al., 2006; Visel
et al., 2004), as these genes provide a new source of driver
sequences for selective SSR delivery.
While this primer focuses on how SSR technologies are
advancing the field of molecular neuroanatomy, other
technologies are being developed and are having major
impact, such as the use of inducible enhancers/promoters
to gain temporal control of transgene transcription (in con-
trast to the posttranslational induction of recombinase
activity described above). For example, an interferon-
responsive promoter (Kuhn et al., 1995) or tetracycline
(tet) responsive elements (TREs) partnered with their
respective transactivators have proven quite powerful,
especially because expression of the target transgene is
reversible (Furth et al., 1994; Gossen and Bujard, 1992;
Hasan et al., 2001; Kistner et al., 1996; Schonig and Bu-
jard, 2003). Incorporating into these approaches an SSR
as the induced effector molecule is providing another
means by which loxP- and/or FRT-containing genes can
be modified with temporal control (Belteki et al., 2005;
Lindeberg et al., 2002; Park et al., 2004; Schonig et al.,
2002; Utomo et al., 1999; Yu et al., 2005).
Going from Cell Fate to Cell Function
by Way of the Three ‘‘Gs’’
Once genetic lineage and anatomical maps are defined,
a next critical step will be to add to them knowledge of cel-
lular behavior, connectivity, and function. Fortunately, the
genetic fate-mapping approaches presented (single, dual,
and inducible strategies), which have been so instrumen-
tal in relating molecular expression to cell fate in the brain,
may serve as a template for a new set of tools capable of
revealing additional attributes of the mapped genetic line-
ages. For example, SSR-based strategies might incorpo-
rate into the target transgene (for example, into an easy to
use modular base vector; Figure 5A) various genetically
encoded effector molecules (Figure 5B), in addition to or
in lieu of reporters. A number of effector molecules hold
great promise for their incorporation into this general
type of SSR-based strategy because some degree of effi-
cacy has already been established in mice. These include
trans-synaptic tracers (Braz et al., 2002; Coen et al., 1997;
Farago et al., 2006; Horowitz et al., 1999; Kissa et al.,
2002; Maskos et al., 2002; Sakurai et al., 2005; Yoshihara,
2002; Yoshihara et al., 1999) that can be used to map
functional afferent and efferent connections of molecularly
distinct neuron classes; neuromodulators (Bond et al.,
2000; Ehrengruber et al., 1997; Johns et al., 1999; Kar-
pova et al., 2005; Slimko et al., 2002; Sutherland et al.,
1999; Tan et al., 2006; Yamamoto et al., 2003; Yu et al.,
2004) that allow one to control the activity of discrete
circuits as a means to assess their roles in development,
perception, behavior, and/or cognition; cell-death-induc-
ing molecules that could allow physiological functions to
Neuron
PrimerFigure 5. Turning Genetic Fate Maps into Functional Connectivity Maps Using SSR Technology as Template
(A) Schematic of a modular, ‘‘plug-and-play’’ vector designed for assembly of dual recombinase-responsive transgenes that offer highly selective,
conditional expression of effector molecules of choice (J.C.K. and S.M.D., unpublished reagent). BAP, broadly active promoter (for example,
CAG/R26); MCS, multiple cloning sites; STOP, transcriptional stop cassette; loxP site, triangle; FRT site, vertical rectangle; sequence encoding an
effector molecule and pA, red rectangle.
(B) A sample of ‘‘plug-in’’ genetically encoded effector molecules that have shown some degree of efficacy in mice.be revealed through targeted cell loss and, in this
manner, produce neurodegenerative disease models
(Breitman et al., 1990; Buch et al., 2005; Burnett et al.,
2004; Chen et al., 2004; Clark et al., 1997; Heyman
et al., 1989; Isles et al., 2001; Kobayashi et al., 1995;
Leuchtenberger et al., 2001; Mallet et al., 2002; Palmiter
et al., 1987; Saito et al., 2001); potential fate-specification
genes that could shed light on genetic programs that can
drive or instruct the development of particular types ofneurons. The effector could also be a molecule that acts
to reversibly modify the expression of another target
transgene. For example, the effector could be the tran-
scriptional activator rtTA, enabling tet-regulated (and
therefore temporally regulated and reversible) expression
of a TRE-driven transgene (Belteki et al., 2005), with the
cell-type selectivity enabled through intersectional activa-
tion of rtTA expression. Indeed, the possibilities seem
without limit.Neuron 54, April 5, 2007 ª2007 Elsevier Inc. 29
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by Way of the Three ‘‘Gs’’
The ability to induce genemodifications at virtually any de-
sired time during the life of an animal is extremely powerful
because it permits investigations to reach beyond the first
required function of a gene. This can translate into an im-
portant capability—gene functions, in many cases, can be
assessed specifically in the postnatal or adult brain. In-
deed, this presents many potential options for studying
adult neurological disease. For example, neurological
phenotypes, especially those resulting from inherited, sin-
gle-gene mutations, can be examined for reversibility fol-
lowing gene repair induced postnatally. In other words, it
becomes possible to ask whether cellular damage done
during development, due to inherited gene inactivation,
is irrevocable or whether it can be rectified postnatally fol-
lowing gene repair. This approach was recently applied to
theMecp2 genewith remarkable results—postnatal rever-
sal of aspects of the autism (Rett)-like neurological pheno-
type (Guy et al., 2007). An inactive Mecp2 gene, silenced
via insertion of a lox-stop cassette, was conditionally
repaired postnatally by cassette deletion (similar to the
strategy schematized in the lower half of Figure 1B); a
CAG-cre-ER-LBD transgene along with tamoxifen admin-
istration provided the genetic access to mediate gene re-
pair in 80% of the cells in the brain. Understanding the
potential for disease reversibility is of course critical
when thinking about possible future therapeutic ap-
proaches. This is but one illustration of howSSRs together
with the three Gs are impacting fundamental disease
issues.
In conclusion, mastering the subjects of reading, writ-
ing, and arithmetic opens aworld of possibility. Embracing
the subjects of genetic access, genetic lineage, and ge-
netic anatomy could have unlimited reward for the field
of molecular neuroscience.
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